BR112018014908A2 - vacina de opioide sintético - Google Patents

vacina de opioide sintético

Info

Publication number
BR112018014908A2
BR112018014908A2 BR112018014908-0A BR112018014908A BR112018014908A2 BR 112018014908 A2 BR112018014908 A2 BR 112018014908A2 BR 112018014908 A BR112018014908 A BR 112018014908A BR 112018014908 A2 BR112018014908 A2 BR 112018014908A2
Authority
BR
Brazil
Prior art keywords
fentanyl
vaccine
drug
analogs
synthetic
Prior art date
Application number
BR112018014908-0A
Other languages
English (en)
Portuguese (pt)
Inventor
D. Janda Kim
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of BR112018014908A2 publication Critical patent/BR112018014908A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112018014908-0A 2016-01-21 2017-01-18 vacina de opioide sintético BR112018014908A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281262P 2016-01-21 2016-01-21
US62/281,262 2016-01-21
PCT/US2017/013865 WO2017127390A1 (en) 2016-01-21 2017-01-18 Synthetic opioid vaccine

Publications (1)

Publication Number Publication Date
BR112018014908A2 true BR112018014908A2 (pt) 2018-12-18

Family

ID=59362842

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018014908-0A BR112018014908A2 (pt) 2016-01-21 2017-01-18 vacina de opioide sintético

Country Status (7)

Country Link
US (1) US11305010B2 (cg-RX-API-DMAC7.html)
EP (1) EP3405475B1 (cg-RX-API-DMAC7.html)
JP (1) JP2019506390A (cg-RX-API-DMAC7.html)
CN (1) CN108884127A (cg-RX-API-DMAC7.html)
BR (1) BR112018014908A2 (cg-RX-API-DMAC7.html)
RU (1) RU2018130106A (cg-RX-API-DMAC7.html)
WO (1) WO2017127390A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660331B2 (en) 2017-11-09 2023-05-30 The Scripps Research Institute Heroin vaccine
WO2020006563A1 (en) * 2018-06-29 2020-01-02 Marquette University Fluorinated compounds as ph-sensitive analgesics
WO2021092446A1 (en) * 2019-11-08 2021-05-14 Regents Of The University Of Minnesota Fentanyl hapten, fentanyl hapten-conjugates, and methods for making and using
US20230100186A1 (en) * 2020-01-13 2023-03-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Fentanyl haptens for the preparation of a fentanyl vaccine
CA3175295A1 (en) * 2020-03-13 2021-09-16 Regents Of The University Of Minnesota Fentanyl haptens, fentanyl hapten conjugates, and methods for making and using
JP7839789B2 (ja) * 2020-11-10 2026-04-02 ザ スクリプス リサーチ インスティテュート オピオイド治療用抗体
US20240307517A1 (en) * 2021-05-10 2024-09-19 Cornell University Development of a highly efficient second generation fentanyl-conjugate vaccine to treat fentanyl addiction
WO2024215826A2 (en) * 2023-04-13 2024-10-17 Avicenna Biotech Research, Llc Compositions and methods for treating fentanyl dependence

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283066A (en) * 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
EP0635019B1 (en) 1992-04-06 1999-05-26 Biosite Diagnostics Inc. Opiate derivatives and protein and polypeptide opiate derivative conjugates and labels
US6262265B1 (en) 1999-06-18 2001-07-17 Microgenics Corporation Non-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay
ATE358275T1 (de) * 2001-11-16 2007-04-15 Randox Lab Ltd Verfahren und kit zum nachweis, oder zum quantifizieren von, metaboliten von fentanyl und metaboliten von fentanyl analoga
NZ537003A (en) * 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
WO2004111202A2 (en) * 2003-03-07 2004-12-23 Incyte Corporation Neurotransmission-association proteins
MXPA04006617A (es) 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.
CA2597098C (en) * 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
US20110182918A1 (en) * 2008-06-13 2011-07-28 Nabi Biopharmaceuticals Personalized drug treatment and smoking cessation kit and method
US9296802B2 (en) * 2009-04-15 2016-03-29 Postech Academy-Industry Foundation Target-specific non-antibody protein and method for preparing the same
MX361929B (es) * 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
AU2012327223A1 (en) * 2011-11-30 2013-06-20 Wellstat Diagnostics, Llc. Assays, antibodies, immunogens and compositions related to 5-FU
CA2895702C (en) 2011-12-21 2020-03-31 The Scripps Research Institute Heroin haptens, immunoconjugates and related uses
US20140093525A1 (en) * 2012-09-17 2014-04-03 Minneapolis Medical Research Foundation Compositions and methods of treating opioid addiction
US9981043B2 (en) 2013-02-08 2018-05-29 Regents Of The University Of Minnesota Analgesic conjugates
US9213029B2 (en) * 2013-06-25 2015-12-15 Samsung Electronics Co., Ltd. Method for diagnosing breast cancer by detection of polymeric immunoglobulin receptor in vesicles isolated from patients

Also Published As

Publication number Publication date
WO2017127390A1 (en) 2017-07-27
RU2018130106A (ru) 2020-02-21
CN108884127A (zh) 2018-11-23
US20210128720A1 (en) 2021-05-06
JP2019506390A (ja) 2019-03-07
CA3015336A1 (en) 2017-07-27
EP3405475B1 (en) 2022-09-28
EP3405475A4 (en) 2019-08-28
RU2018130106A3 (cg-RX-API-DMAC7.html) 2020-05-26
US11305010B2 (en) 2022-04-19
EP3405475A1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
CY1124787T1 (el) Αντισωματα anti-gitr και μεθοδοι χρησης αυτων
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
Kim et al. Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection
WO2017097723A3 (en) Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
EP3831944A4 (en) MONOCLONAL ANTIROR1 ANTIBODY, FUNCTIONAL FRAGMENT OF IT, GENE, DRUG DELIVERY COMPOSITION AND PHARMACEUTICAL COMPOSITION
Gillard et al. An assessment of prime‐boost vaccination schedules with AS03A‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults
Rudenko et al. H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus
MX2017009047A (es) Regimen de dosificacion para antagonistas de madcam.
Lazarus et al. Innate and adaptive immunity in immune thrombocytopenia
MA50488B1 (fr) Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
CL2017001859A1 (es) Inhalador de polvo seco que comprende propionato de fluticasona y xinafosfato de salmeterol
Mohapatra et al. In silico screening of phytochemicals of Ocimum sanctum against main protease of SARS-CoV-2
JP2019506390A5 (cg-RX-API-DMAC7.html)
Maxmen First proven malaria vaccine rolled out in Africa--but doubts linger.
Bird Statins as adjuvants
Seidel et al. A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens
Wennerberg et al. Adenosine regulates radiation therapy-induced anti-tumor immunity
MX2023004718A (es) Antigeno quimerico que comprende el dominio extracelular de pd-l1.
AR029336A1 (es) Peptidos utiles para preparar medicamentos para el tratamiento, prevencion o mejoramiento de estados alergicos, inmunogenos,epitopos y mimotopos, vacunas, ligandos, composiciones farmaceuticas; uso de los peptidos ,de los ligandos en la preparacion de medicamentos; proceso para preparar vacunas y pr
MX2022005245A (es) Regimen de dosificacion de anticuerpos anti-cd27 para el tratamiento de cancer.
Waqar et al. Influenza vaccination in patients with cancer: an overview
Ganguly et al. Biomedicine and biotechnology: Public health impact
Mori et al. Underlying mechanisms of methamphetamine-induced self-injurious behavior and lethal effects in mice
Martoni et al. Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg)+ dexamethasone in the prevention of acute cis-platinum-induced emesis.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements